Salhi Houda, Lahlou Asmae, Dante Mamadou L, El Ouahabi Hanan, Boujraf Saïd, Ajdi Farida
Department of Endocrinology and Diabetology, University Hospital of Fez, Fez, Morocco.
Department of Biophysics and Clinical MRI Methods, Faculty of Medicine and Pharmacy, University of Fez, Fez, Morocco.
J Family Med Prim Care. 2018 Sep-Oct;7(5):963-966. doi: 10.4103/jfmpc.jfmpc_207_16.
Stature-weight growth delay (SWGD) is a frequent motivation of consultation. It could be a consequence of a known chronic affection, congenital or acquired affection. The purpose of this study is to describe epidemiological, clinical, paraclinical, and etiological aspects of SWGD.
This retrospective study included 103 patients presenting a growth delay with an average age of 14.44 years and ranging between 5 and 21 years. Male predominance was noticed in 68.93% of cases. Patients showed a stature lower to -2 standard deviation (SD) for corresponding age compared to Sempe and Pedron reference. Patients were hospitalized in Endocrinology and Metabolic Diseases Department of the University Hospital of Fez, Fez, Morocco.
Patient's history included a perinatal suffering in 6.7% of cases, a chronic pathology follow-up in 17.6% of cases, and psychomotor development disorder in 10.6% of cases. The average weight was -2.37 SD with extremes varying from -4 to -0.5 SD. The stature values varied between -4.5 and -2 SD for the given age, with an average of -3.12 SD. A severe stature delay (< -3 SD) was recorded in 39.6% of cases and the targeted average size was -2.44 SD with extremes varying from -4 to -1.5 SD. Growth delay etiologies were dominated by a deficit in growth hormones (GHs) in 60% of cases.
Dynamic tests objectified a total deficit and partial deficits in GH in 41.7 and 30% of patients, respectively. The hypothalamo-pituitary magnetic resonance imaging was pathological in 23.3% of patients and showed a syndrome of interruption of pituitary stem in seven patients, pituitary hail gland in three patients, a craniopharyngioma in two patients, prolactin microadenoma in one patient, and nonfunctional pituitary microadenoma in one patient. GH treatment was established in 16 children that were presenting a deficit in GH, and two girls presenting Turner syndrome, whereas etiological treatment was suggested in all remaining cases.
身高体重增长延迟(SWGD)是常见的就诊原因。它可能是已知慢性疾病、先天性或后天性疾病的结果。本研究的目的是描述SWGD的流行病学、临床、辅助检查和病因学方面。
这项回顾性研究纳入了103例生长延迟患者,平均年龄为14.44岁,年龄范围在5至21岁之间。68.93%的病例中男性占优势。与Sempe和Pedron参考标准相比,患者的身高低于相应年龄的-2标准差(SD)。患者在摩洛哥非斯大学医院内分泌与代谢疾病科住院。
患者病史包括6.7%的病例有围产期疾病,17.6%的病例有慢性疾病随访史,10.6%的病例有精神运动发育障碍。平均体重为-2.37 SD,极值在-4至-0.5 SD之间。给定年龄的身高值在-4.5至-2 SD之间,平均为-3.12 SD。39.6%的病例记录有严重身高延迟(<-3 SD),目标平均身高为-2.44 SD,极值在-4至-1.5 SD之间。生长延迟病因以60%的病例中生长激素(GHs)缺乏为主。
动态试验分别在41.7%和30%的患者中发现GH完全缺乏和部分缺乏。下丘脑-垂体磁共振成像在23.3%的患者中呈病理性,7例患者显示垂体柄中断综合征,3例患者显示垂体冰雹样腺体,2例患者显示颅咽管瘤,1例患者显示泌乳素微腺瘤,1例患者显示无功能垂体微腺瘤。16例GH缺乏的儿童和2例特纳综合征女孩接受了GH治疗,其余所有病例均建议进行病因治疗。